Atamestane

Atamestane (developmental code name SH-489), also known as metandroden, as well as 1-methylandrosta-1,4-diene-3,17-dione, is a steroidal aromatase inhibitor that was studied in the treatment of cancer.[1] It blocks the production of estrogen in the body. The drug is selective, competitive, and irreversible in its inhibition of aromatase.[2]

Atamestane
Clinical data
Other namesSH-489; Metandroden; 1-Methylandrosta-1,4-diene-3,17-dione
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC20H26O2
Molar mass298.419 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

See also
  • Boldione (androsta-1,4-diene-3,17-dione)

References
  1. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 794–. ISBN 978-1-4757-2085-3.
  2. el Etreby MF (March 1993). "Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review". J. Steroid Biochem. Mol. Biol. 44 (4–6): 565–72. doi:10.1016/0960-0760(93)90260-4. PMID 7682838.
  • Atamestane entry in the public domain NCI Dictionary of Cancer Terms

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.